BSGM
Health Care

BioSig Technologies, Inc.

BSGM
Since

Headquarters:

CT, United States

Exchange:

NASDAQ

Industry:

Medical Devices

Number of Employees:

4.00

Current Fiscal Year:

2024

Market Cap:

17.75M

Price per Share:

$1.03

Quarterly Dividend per Share:

Year-to-date Performance:
-26.4286%
Dividend Yield:
%
Price-to-book Ratio:
-59.17
Trailing P/E Ratio:
N/A

Price History

Latest Prices

DateOpenHighLowClose
2025-04-301.011.040.92251.03
2025-04-2911.050.920.9201
2025-04-280.921.140.921.04
2025-04-250.82010.94990.720.92
2025-04-240.620.89990.620.84

BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body's electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company's product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Financial Performance

2024 Revenue:39.00K

Detailed view of quarterly revenue

2024 Net Income:-15.28M

Detailed view of quarterly net income

2024 Free Cash Flow:-7.23M

Overview of free cash flow for the quarter

Annual Revenue Comparison

Compares total annual revenues

Similar Companies

Health Care
IRTC
iRhythm Technologies, Inc.
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
3.35B
Market Cap
*Data based on the last 12 months.